POS0748 EASY-BILAG: A NEW TOOL FOR FASTER AND MORE ACCURATE RECORDING OF BILAG-2004 DISEASE ACTIVITY IN SLE

Background: BILAG-2004 index is an important disease activity instrument for SLE which widely used in clinical trials and treatment commissioning. It more comprehensive responsive than SLEDAI. However, may be difficult or time-consuming to complete during routine clinic visits. To derive the eventual scores from A (highly active) E (no current prior involvement) each of 9 organ domains, relies on a separate form, glossary scoring algorithm. Objectives: The Easy-BILAG project aimed develop validate simplified tool original rapidly accurately care. Methods: Data UK BILAG-Biologics Registry (BILAG-BR) were measure frequency with 97 items occurred population active SLE. These data series prototypes draft new - “Easy-BILAG”. After preliminary testing, validation study was conducted test accuracy, speed usability compared standard template. Rheumatologists specialty trainees centres around invited score timed workbook 10 exemplar case vignettes, using either reference documents. vignettes tested clinicians both frequent uncommon manifestations as well longitudinal flare remission. All workbooks contained overview detailed instructions BILAG-2004. Results: Among 2395 submissions BILAG-BR 6 most frequently scored present 20% records; arthralgia (72%), mild skin eruption (47%), moderate arthritis (38%), mucosal ulceration (34%), alopecia pleurisy / pericarditis (22%). Twenty-five less 1% assessments. therefore designed enhance visibility capture all >5% rapid single-page assessment. remaining, common items, are scored, only when necessary, second page. incorporates abridged definition immediately adjacent item. colour-blindness compatible, colour-coding system directs instantly overall A-E domain. In exercise, asked identify assign scores, A-E, domains vignettes. Twenty clinicians, range experience, have so far participated. working documents (n = 11), took 90 +/- minutes (mean SEM) complete. Clinicians 9) completed exercise significantly faster at 66 8 (p 0.05). Crucially, yielded higher percentage accuracy 95.3 0.8 % across 81.8 6.2 achieved by documentation difference apparent specifically comparing where exercises registered disease. Here, showed no decline 94.9 1.0 75.7 5.3% 0.005). survey, (9/9) testing template rated it intuitive simple navigate. Conclusion: facilitates accurate provides format amenable use practice. Following completion validation, will made available clinicians. Figure 1. Illustration shows format, colour scheme method highest prevalence mucocutaneous musculoskeletal Disclosure Interests: Lucy Marie Carter: None declared, Caroline Gordon: Chee-Seng Yee: Ian N. Bruce Speakers bureau: GlaxoSmithKline, UCB Pharma, Consultant of: AstraZeneca, Eli Lilly, ILTOO MedImmune, Merck Serono, Grant/research support from: Genzyme Sanofi, David Isenberg: Sarah Skeoch: Edward Vital Roche, GSK AstraZeneca